Kornimate/medical-research-clean huggingface dataset:
antineoplaston therapy in treating patients with primary central nervous system lymphoma

Conditions: Primary Central Nervous System Lymphoma

Summary: rationale: antineoplastons are naturally-occurring substances that may also be made in the laboratory. antineoplastons may inhibit the growth of cancer cells. purpose: this phase ii trial is studying how well antineoplaston therapy works in treating patients with primary central nervous system lymphoma.

objectives: * assess the safety and possible effectiveness of antineoplastons a10 and as2-1 in patients with serious or immediately life-threatening primary central nervous system lymphoma. * describe response to, tolerance to, and side effects of this regimen in these patients. outline: this is an open-label study. patients receive gradually escalating doses of intravenous antineoplaston a10 and antineoplaston as2-1 6 times per day until the maximum tolerated dose is reached. treatment continues for at least 12 months in the absence of disease progression or unacceptable toxicity. after 12 months, patients with responding or stable disease may continue treatment. tumors are measured every 2 months for 6 months, every 3 months for 2 years, every 6 months for years 3 and 4, and then annually for years 5 and 6. projected accrual: a total of 20-40 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed stage i-iv primary central nervous system lymphoma for which no curative therapy exists * measurable tumor by mri or ct scan * tumor must be greater than 2 cm in largest diameter patient characteristics: age: * 18 and over performance status: * karnofsky 60-100% life expectancy: * at least 2 months hematopoietic: * wbc greater than 2,000/mm\^3 * platelet count greater than 50,000/mm\^3 hepatic: * bilirubin no greater than 2.5 mg/dl * sgot and sgpt no greater than 5 times upper limit of normal * no hepatic insufficiency renal: * creatinine no greater than 2.5 mg/dl * no history of renal conditions that contraindicate high dosages of sodium cardiovascular: * no cardiac insufficiency * no hypertension * no history of congestive heart failure * no history of other cardiovascular conditions that contraindicate high dosages of sodium other: * not pregnant or nursing * fertile patients must use effective contraception during and for at least 4 weeks after study participation * no serious infection requiring antibiotics, antifungals, or antivirals prior concurrent therapy: biologic therapy: * at least 4 weeks since prior immunotherapy and recovered * no concurrent immunomodulatory agents (e.g., interferon or interleukin-2) chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered * no concurrent antineoplastic agent endocrine therapy: * concurrent corticosteroids allowed * must be on stable dose for at least 4 weeks prior to study entry radiotherapy: * at least 8 weeks since prior radiotherapy and recovered surgery: * not specified other: * no prior antineoplastons
the efficacy of external warming during laparoscopic bariatric surgery

Conditions: Hypothermia; Morbid Obesity; Bariatric Surgery Candidate

Summary: external warming is routinely used in general surgery to offset the deleterious effects of hypothermia. it entails deployment of a disposable, external heating blanket attached to a regulated hot-air pump. the need for external warming in the morbidly obese population undergoing short laparoscopic procedures is unclear. if proven to be unnecessary, time and momentary costs could be lowered. the study will compare core-temperature dynamics during laparoscopic bariatric procedures anticipated to last \<2h. the study group will be left without a warming blanket while the control group will receive routine external warming. post-anesthesia care unit (pacu) arrival temperature will also be recorded.


Eligibility criteria:
inclusion criteria: * eligible for bariatric surgery * surgery time estimated to be \< 2 hours exclusion criteria: * previous abdominal surgeries (except laparoscopic cholecystectomies, appendectomies and hysterectomies+/-oophorectomies). * surgery time estimated to be more than 2 hours

Keywords: sleeve gastrectomy roux-y gastric bypass single anastomosis gastric bypass hypothermia external heating blanket
local anesthetic response in ehlers-danlos syndrome (eds) and healthy volunteers

Conditions: Ehlers-Danlos Syndrome; Anesthesia, Local

Summary: local anesthetic resistance is commonly reported by patients with eds. however, there are no objective data on the occurrence of local anesthetic resistance in eds patients and in healthy volunteers. we propose to collect such objective data on the frequency of drug resistance and whether any problems with local anesthesia are due to initial ineffectiveness or due to its effects dissipating too soon.

there was a prior large online questionnaire to better understand the issues around local anesthetic resistance. by november 2018, 933 eds patients (total 1059 respondents) completed the survey, 99.2% of which had previously received local anesthetics. among these patients, 88% reported that they have "had a problem with local anesthetic injection not working adequately or properly," while only 54% of respondents without eds reported a similar problem. these data suggests that local anesthetic resistance might be more prevalent in patients with eds than in the general population. if these findings are true, then this might have significant implications for the appropriate management of these patients during minor surgery and dental procedures. this study aims to assess the frequency and related issues around local anesthetic resistance in eds patients, including whether the problem is a lack of analgesia or a timing effect (short duration of action or delayed onset of action), and whether the problem relates only to some local anesthetics or whether there is a problem with the whole class of local anesthetics.

Eligibility criteria:
inclusion criteria: * eds patients, clinically diagnosed hypermobile eds based on 2017 criteria * eds patients with genetically proven non-hypermobile eds * healthy participants, no eds * able and willing to provide informed consent exclusion criteria: * known allergy to lidocaine or bupivacaine * unable to provide informed consent

Keywords: ehlers-danlos syndrome local anesthesia resistance
patients characteristics, treatment pattern & outcomes of patients with advanced, recurrent or metastatic endometrial carcinoma

Conditions: Oncology; Endometrial Cancer; Advanced Cancer; Recurrent Cancer; Metastatic Cancer

Summary: this is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.


Eligibility criteria:
inclusion criteria: 1. adult women ≥ 18 years at index date. 2. documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. patients with interval surgery after primary ct may be eligible. 3. index date should represent at least the first\* or second line\*\* chemotherapy systemic treatment and occur between, 1, january 2019 and 31, december 2019. 4. do not express refusal to her personal data processing or did not express her refusal for deceased patients. exclusion criteria: 1. no clinical records for tumor imaging or administration of anti-cancer therapy. 2. patients with active malignancy other than ec cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion. 3. patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased). 4. patient did not receive chemotherapy systemic treatment. 5. patient undergo treatment by pembrolizumab or another immunotherapy in first line (cohort 1) or second line (cohort 2) during the eligibity (inclusion) period.
peri-neural dexmedetomidine versus dexamethasone for supraaclavicular block adjuvant to bupivacaine supraclavicular brachial plexus block

Conditions: Brachial Plexus Block

Summary: to assessthe impact of addition of dexmedetomidine or dexamethasone to bupivacaine, on duration of analgesia (time in hours to the first report of postoperative pain )at the surgical site

this randomized, controlled double blinded study included 42 adult patients undergoing arteriovenous fistula surgery. ultrasound-guided supraclavicular brachial plexus block was initiated after placement of full monitoring . supraclavicular brachial plexus block was achieved with the use of total volume 32 ml of anesthetic drugs in all patients. bupivacaine 30 ml 0.25% was combined with 2 ml normal saline (control group a, n=14), bupivacaine 30 ml 0.25% was combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline ( dexmedetomidine group b ,n=14), or bupivacaine 30 ml 0.25% was combined with 4 mg peri neural dexamethasone (2 ml) ( dexamethasone group c, n=14).the onset and duration of sensory and motor blocks, the time to first request to postoperative rescue analgesic, richmond agitation-sedation score, hemodynamic data, visual analogue pain scores, were reported at predetermined time assessment points. postoperative rescue intravenous fentanyl consumption over 24 hours and complications occurred were recorded.

Eligibility criteria:
inclusion criteria: * all the patients included in the study aged 18 to 60 years old were on chronic hemodialysis and they had a hemodialysis session one day before the block performance exclusion criteria: * neurological, neuromuscular, psychiatric disorders, hepatic, respiratory, or cardiac diseases; coagulation disorders; infection at the block injection site; patients with a body mass index more than 35; or patients who refused the procedure

Keywords: dexmedetomidine dexamethasone
semi-automatic download of prostate biopsy cores while keeping the orientation, unfolding and unity of the sample

Conditions: Prostate Cancer

Summary: performance evaluation of a novel, semi-automated device and method for needle core biopsy download compared to standard methods in terms of: 1. biopsy core length obtained (i.e. collecting all tissue fragments) 2. biopsy core yield (i.e. percent of tissue loss during the pathologic processing) 3. pathologist interpretability 4. processing time 5. prostate cancer detection.


Eligibility criteria:
inclusion criteria: * age 18 years or older * planned for radical or open prostatectomy operation or planned for trus prostate biopsy procedure. * signed informed consent. exclusion criteria: * patient's unwilling to participate.
a phase ii clinical study of epigallocatechin-3-gallate in patients with esophageal squamous cancer

Conditions: Esophageal Cancer; Dysphagia, Esophageal; Epigallocatechin Gallate

Summary: the investigators conduct this phase ii study to evaluate safety and effectiveness of egcg in patients with dysphagia. swallowing-related dysphagia and pain scores were recorded using the numerical rating scale (nrs) daily . barium meal radiography was utilized to measure the luminal size and the length of the lesion area both before and after a week of egcg treatment. the scales are translated into chinese and guides in chinese are developed instructing how to use the scales and perform the assessments.


Eligibility criteria:
inclusion criteria: * confirmed pathological esophageal squamous cell carcinoma * ≥18 years old * the eastern cooperative oncology group performance status (ecog ps) 0-1 * no previous anti-tumor treatment * no esophageal bleeding or fistula * adequate hemocyte count, normal hepatic and renal functions * esophageal obstruction classified as grade 2 or grade 3 according to stooler's dysphagia score exclusion criteria: * lactating or pregnant women * known hypersensitivity or allergy to any kind green tea extract * placement of small intestinal feeding tube or endoscopic stent treatment * unable or refusing to take oral liquids

Keywords: esophageal cancer dysphagia, esophageal epigallocatechin gallate
phase 2a study of prv-6527 in subjects with moderately to severely active crohn's disease

Conditions: Crohn's Disease

Summary: this study will evaluate the efficacy and safety of oral prv-6527 in the treatment of moderately to severely active crohn's disease

this is a phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with moderately to severely active crohn's disease. eligible subjects include males and females aged 18-75 years with moderately to severely active cd for at least 3 months. each subject will receive the assigned treatment over 12 weeks, followed by a 4-week safety follow-up period.

Eligibility criteria:
inclusion criteria: 1. subject must be a man or woman between 18 years and 75 (inclusive) years of age. 2. has moderate to severe cd and a histologic diagnosis of cd for at least 3 months before screening. exclusion criteria: 1. has other gastrointestinal inflammatory diseases. 2. has any malignancy or lymphoproliferative disorder other than nonmelanoma cutaneous malignancies or cervical carcinoma in situ that has been treated with no evidence of recurrence. 3. has colon cancer or severe dysplasia. subjects with cd for ≥8 years involving the colon are not excluded if they had a colonoscopy to assess for the presence of dysplasia within 1 year before baseline or if they had a colonoscopy at the screening visit that excludes any evidence of malignancy. 4. has current signs or symptoms of an acute infection or infected skin wounds or ulcers, with the exception of nonserious infections in the opinion of the investigator (e.g. sepsis, pneumonia, or pyelonephritis), including any infection requiring hospitalization or iv antibiotics, within 8 weeks before baseline. 5. has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or signs and symptoms thereof. 6. has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

Keywords: crohn's disease
ifosfamide/carboplatin/etoposide/rituxan followed by zevalin in relapsed/refractory intermediate grade b-cell lymphoma

Conditions: Non-Hodgkins Lymphoma

Summary: in this multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90y zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade b-cell non-hodgkin's lymphoma.

upon determination of eligibility, patients will receive: * ifosfamide + carboplatin + etoposide + rituximab patients showing no response to this combination regimen will receive 90y zevalin after two cycles or when progression is clearly documented. in responding patients, four cycles will be administered, followed by 90y zevalin.

Eligibility criteria:
inclusion criteria: to be included in this study, you must meet the following criteria: * intermediate grade cd20-positive b-cell non-hodgkin's lymphoma * persistent lymphoma after one or two previous chemotherapy regimens * patients should not be considered candidates for high-dose chemotherapy * ability to perform activities of daily living with assistance * measurable or evaluable disease * age \> 18 years * adequate bone marrow, liver and kidney function exclusion criteria: you cannot participate in this study if any of the following apply to you: * patients with impaired bone marrow reserve * female patients who are pregnant or lactating * serious active infection at the time of treatment * any other serious underlying condition * brain or meningeal) with lymphoma * hiv or aids-related lymphoma * received external beam radiation therapy to \> 25% of active bone marrow. * history of other cancers, either active or treated please note: there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
development of a clinical prediction rulefor neck manipulation

Conditions: Mechanical Neck Pain

Summary: cervical spine manipulation has been shown to be helpful for some patients with neck pain. this study sought to determine factors which were predictive of which patients with neck pain would benefit from manipulation.


Eligibility criteria:
inclusion criteria: * age 18 to 60 years * primary report of neck pain with or without unilateral upper extremity symptoms * baseline neck disability index score of 10 points (out of 50) or greater exclusion criteria: * any medical red flags suggesting that the etiology of symptoms might be nonmusculoskeletal * diagnosis of cervical spinal stenosis (as identified in the patients' medical intake form) * bilateral upper extremity symptoms * evidence of central nervous system involvement * history of whiplash injury within 6 weeks of the examination * pending legal action regarding their neck pain * 2 or more positive neurologic signs consistent with nerve root compression (changes in sensation, myotomal weakness, or decreased deep tendon reflexes) * any history of cervical spine surgery, rheumatoid arthritis, osteoporosis, osteopenia, or ankylosing spondylitis.
drawing as a measurement of dental anxiety

Conditions: Dental Anxiety

Summary: in the present study, we aimed to assess children's anxiety levels by using different dental anxiety scales and children's drawings evaluated according to two different scoring systems: child drawing: hospital (cd: h) and emotional indicators of human figure drawings (hfd).

background: drawings can be used as a method of communication that represents an individual's self-concept, anxiety, attitude, or conflict. aim: the purpose of this study was to evaluate children's drawing as a measure of dental anxiety in a dental setting. design: seventy- eight children, aged 6-12 years, were enrolled in this study. pulp therapy and/or restorative treatment was performed during the first therapeutic session for all participants. sound, eye, and motor (sem) and frankl scales were used as an objective assessment of dental anxiety during treatment. after the treatment session, the children were instructed to draw a picture of a person at a dental clinic. children's drawings were scored by a paediatric dentist and a psychologist using child drawing: hospital (cd: h) scale and emotional indicators of human figure drawings (hfd). the findings were compared with frankl and sem scores.

Eligibility criteria:
inclusion criteria: * 6-12 years of age-independent of sex, and ethnic characteristics * children without previous dental treatment experience. * children with carious primary teeth which required pulp therapy and restorative treatment * children who are not considered medically compromised * obtained written informed consent from parents or caregivers and obtained verbal informed consent from the child for their participance in the study where procedures are explained in an age-appropriate attitude * children who accept to draw a picture exclusion criteria: * children with a compromised physical and mental health history * children who already received dental treatments * children who only needed preventive treatments * children who reject to draw a picture

Keywords: drawing children dental anxiety
assessment of the knowledge and needs of patients with amd before a therapeutic patient education program is put in place

Conditions: Age-related Macular Degeneration (AMD)

Summary: age-related macular degeneration (amd) is a disease that blurs the sharp, central vision you need for "straight-ahead" activities such as reading, sewing, and driving. amd affects the macula, the part of the eye that allows you to see fine detail the purpose of the study is to describe in patients with amd and depending on the nature of their pathology (neovascular or atrophic): (i) knowledge about their pathology (risk factors, symptoms, treatments, self-monitoring tool), (ii) their needs and (iii) impact on their daily lives this study is to make an inventory of the knowledge of patients with amd about their disease and risk factors using a questionnaire (appendix 1) and to identify their needs, the impact of the disease on their daily lives during individual interviews by raising the recurrent data and confronting them during the focus group. the information gathered will enable the construction of a therapeutic education program for better patient care and to strengthen the patient's capacities so that he becomes an actor in his change throughout his care project. this a 3 steps study: 1. 200 patients will be enrolled and answer a questionnaire on knowledge of the disease 2. two groups of 20 patients will be selected to participate to a semi-structured individual interviews 3. two focus groups of 10 patients will be organized to assess needs, expectations, satisfactions or to better understand opinions, motivations or behaviors.


Eligibility criteria:
inclusion criteria: * patient with amd (neovascular and atrophic) whatever the stage of the disease * patient over 50 * patient affiliated to a social security scheme * written informed consent of the patient exclusion criteria: * patient unable to understand the information, fill out the questionnaires * patient with diabetic retinopathy